Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (4968)	11/1/2013 4:54:05 PM
From: scaram(o)uche	of 4974

:-) I'm glad for this post.... Message 29203727 The FDA in general, and CDER under Janet W. with a spotlight, continues as the class-act regulatory agency, while Washington falls down around them. At the same time, an anything-but-conservative stance has been adopted to cancer therapy..... clinicaltrials.gov This sort of experiment reflects how willing FDA is to lube innovation in cancer therapy. So, they are accommodating and, yet, most often get things correct. That seems best for patients on Earth. Good medicines become generic, open the faucet and let them flow. Oooops about the occasional downside, risk:reward and all.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next